Skip to main content

Dan Kidle

Managing Partner

Dan identifies promising investment opportunities across Arboretum’s sectors of interest, with particular emphasis on life science tools. He also works closely with portfolio companies to support strategic decision-making, fundraising efforts, and financial analysis. Dan currently serves as a board director for Jumpcode Genomics, Flosonics Medical, Akadeum Life Sciences, Enumera Molecular and BrightSpec.

Dan has played key roles in successful Arboretum investments, including serving on the board of IntelliCyt (acquired in 2016) and leading Arboretum’s investment, and serving as board chair for both Swift Biosciences (acquired in 2021) and Dropworks (acquired in 2021). Additionally, Dan has supported investments including NeuMoDx, Strata Oncology, and SI-BONE. Dan was a recipient of the National Venture Capital Association’s Rising Star Award in 2020.

Prior to joining Arboretum, Dan held corporate finance roles at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations. Dan currently serves on the Investment Advisory Board for the Michigan Biomedical Venture Fund at the University of Michigan.

Dan earned a BBA and MBA from the Ross School of Business at the University of Michigan.

High resolution photo
CURRENT BOARD SEATS
PREVIOUS PORTFOLIO INVOLVEMENT
  • Dropworks (acquired)
  • IntelliCyt (acquired)
  • NeuMoDx (acquired)
  • Swift Biosciences (acquired)
ACTIVITIES AND AFFILIATIONS
  • Investment Review Board, Ann Arbor SPARK
  • Advisor, Michigan Biomedical Venture Fund, University of Michigan
  • Instructor, NVCA’s VC University
ASSISTANT